













Endoscopic ultrasound-guided ethanol ablation 
of insulinoma
Ewa Zalewska 1, Przemysław Kłosowski1, Michał Dubowik2, Rafał Pęksa3, Krzysztof Sworczak1
1Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
2Department of Gastroenterology and Hepatology, Medical University of Gdansk, Gdansk, Poland
3Department of Pathology, Medical University of Gdansk, Gdansk, Poland
Key words: insulinoma; ethanol ablation; hypoglycemia
Endokrynologia Polska
DOI: 10.5603/EP.a2020.0070
Volume/Tom 71; Number/Numer 6/2020
ISSN 0423–104X
A 72-year-old female patient with a four-month history 
of recurrent episodes of symptomatic hypoglycaemia 
was admitted to the Department of Endocrinology 
and Internal Medicine, Medical University of Gdansk 
(Poland) in November 2019. A month earlier, the patient 
was hospitalised in the Cardiology Department of St. 
Wojciech hospital due to non-ST segment elevation 
myocardial infarction, where a low blood glucose level 
of 2.4 mmol/L was recorded during one of the episodes 
of agitation, excessive sweating, and weakness. In the 
Department of Endocrinology and Internal Medicine, 
insulinoma was confirmed on the basis of clinical pre-
sentation and additional examinations. The starvation 
test was positive. The criteria for endogenous hyper-
insulinaemic hypoglycaemia were met after a fasting 
time of 5 h with the glucose level of 1.8 mmol/l. Diffu-
sion-weighted magnetic resonance imaging revealed 
a 12-mm lesion on the anterior surface of the pancreas, 
which did not show restriction diffusion (Fig. 1A) and 
typical arterial enhancement (Fig. 2B). Endoscopic ul-
trasound (EUS) elastography showed lower elasticity 
of the tumour as compared to that of the surrounding 
pancreatic tissue (Fig. 2). EUS-guided fine-needle aspira-
tion of the lesion was performed to collect material for 
cytological examination. The cellular smears revealed 
a scant to moderate amount of granular cytoplasm, 
which indicated neurosecretory capability (Fig. 3).
The standard treatment for a functional pancreatic 
neuroendocrine tumour is surgical resection [1, 2]. In 
terms of heart failure with low ejection fraction, the 
perioperative risk was high because of recent myocar-
dial infarction with the necessity to continue double 
antiplatelet therapy. Considering this limitation and 
the patient’s severity of symptoms and benign char-
Figure 1. Magnetic resonance imaging of the abdomen revealed a 12-mm lesion on the anterior surface of the pancreas (arrow), 
which did not show restriction diffusion on diffusion-weighted imaging (a) and did not present typical contrast enhancement for 
insulinoma on T1-weighted images (B)
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patient reported mild abdominal pain on the day of 
the procedure, and a transient, six-fold elevation of 
lipase activity was observed, which was normalised 
within 72 h. Another type of nonsurgical management 
of insulinoma is EUS-guided radiofrequency ablation. 
Both ablative therapies, namely ethanol injection and 
radiofrequency, seem to be effective, safe, and repeat-
able procedures in patients who are at increased surgi-
cal risk [1–5]. Mele et al. reported that after an average 
follow-up of 16 months, the overall success rate of 
nonsurgical ablative treatments of insulinoma was 84% 
[4]. The longest follow-up of a patient after a successful 
EUS-guided ethanol ablation of insulinoma was four 
years [5]. It is worth highlighting that ethanol ablation 
is more economically beneficial than EUS-guided radio-
frequency ablation. Clinical trials and longer follow-ups 
are warranted to determine which of these nonsurgical 
ablative techniques achieves the best clinical outcome 
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acteristic of insulinoma in most cases, we proposed 
less invasive treatment [1–5]. The patient underwent 
EUS-guided ethanol ablation of the lesion. Two millili-
tres of 96% ethanol were injected under visual control 
in small aliquots (0.1 mL) until hyperechoic blush was 
seen within the tumour (Fig. 4). After the procedure, 
a partial improvement was observed. The episodes 
of hypoglycaemia occurred less frequently, and the 
symptoms were milder. In January 2020, a second ses-
sion of EUS-guided ethanol ablation was performed, 
and it seemed to be completely effective in a five-month 
follow-up. We did not observe any clinically signifi-
cant adverse effects of the treatment approach. The 
Figure 4. Endoscopic ultrasound-guided ethanol ablation of the 
insulinoma. Two millilitres of 96% ethanol were injected under 
visual control in small aliquots (0.1 mL) until hyperechoic blush 
was seen within the tumour (arrow)
Figure 2. An endoscopic ultrasound elastography revealed lower 
elasticity of the tumour as compared to that of the surrounding 
pancreatic tissue (arrows)
Figure 3. A smear from the pancreatic tumour showing a cellular 
aspirate; numerous isolated cells and sheets of tumour cells 
with overlapping and overcrowding of nuclei; minimal nuclear 
pleomorphism; fine, evenly dispersed nuclear chromatin with 
occasional inconspicuous nucleoli; a scant to moderate amount 
of granular, amphophilic cytoplasm (neurosecretory capability)
